Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

More than 422 million people worldwide have chronic metabolic disease diabetes, according to a report by the UN’s public health agency the World Health Organisation (WHO), which projected that by 2030 the disease will be the seventh leading cause of death. There is currently no cure for either type 1 or type 2 diabetes. The…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.